Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials.
Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction / Bersani, F Saverio; Mellon, Synthia H; Lindqvist, Daniel; Kang, Jee In; Rampersaud, Ryan; Somvanshi, Pramod Rajaram; Doyle, Francis J; Hammamieh, Rasha; Jett, Marti; Yehuda, Rachel; Marmar, Charles R; Wolkowitz, Owen M. - In: MILITARY MEDICINE. - ISSN 0026-4075. - 185:Supplement_1(2020), pp. 311-318-318. [10.1093/milmed/usz260]
Novel Pharmacological Targets for Combat PTSD-Metabolism, Inflammation, The Gut Microbiome, and Mitochondrial Dysfunction
Bersani, F Saverio;
2020
Abstract
Current pharmacological treatments of post-traumatic stress disorder (PTSD) have limited efficacy. Although the diagnosis is based on psychopathological criteria, it is frequently accompanied by somatic comorbidities and perhaps "accelerated biological aging," suggesting widespread physical concomitants. Such physiological comorbidities may affect core PTSD symptoms but are rarely the focus of therapeutic trials.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bersani_Novel Pharmacological Targets_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
367.49 kB
Formato
Adobe PDF
|
367.49 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
